A recent meta-analysis assessing the balance of risk and benefit in CKD indicates that the absolute benefits of SGLT-2 inhibition in terms of kidney disease progression, cardiovascular death or hospitalisation for heart failure, and acute kidney injury substantially outweigh any associated risks in the studied populations (Fig. 1) [4]. Here, SLC5A2 is linked to kidney disorder.